Peer-influenced content. Sources you trust. No registration required. This is HCN.

Neurology Learning NetworkGantenerumab Does Not Slow Cognitive Decline in Early Alzheimer Disease

Gantenerumab’s Impact on Alzheimer’s Disease: A Closer Look at Amyloid Plaque Reduction and Cognitive Outcomes

In a recent advancement in Alzheimer’s disease research, a pair of phase 3 trials examining the efficacy of gantenerumab, a monoclonal antibody targeting amyloid-beta, revealed its limited success in mitigating clinical decline in early-stage patients. Despite not achieving its primary cognitive outcome goals, the trials provided significant insights into the drug’s impact on amyloid plaque burden and other biomarkers, offering a nuanced understanding of its therapeutic potential and implications for future Alzheimer’s treatments.

Key Points:

  • Gantenerumab, a monoclonal antibody targeting amyloid-beta, was evaluated in two phase 3 trials (GRADUATE I and II) involving patients with early Alzheimer disease but did not meet the primary endpoint of slowing clinical decline.
  • Participants in the GRADUATE trials were aged 50 through 90 with mild cognitive impairment or mild dementia, showing evidence of amyloid plaques through PET or CSF testing.
  • Over 116 weeks, the change in Clinical Dementia Rating–Sum of Boxes (CDR-SB) scores was minimal between the gantenerumab and placebo groups, indicating no significant impact on cognitive decline.
  • Despite this, gantenerumab treatment resulted in a substantial reduction in amyloid plaque burden as evidenced by PET, with a percentage of patients achieving amyloid-negative status.
  • The drug was also associated with lower levels of CSF phosphorylated tau 181 and increased Aβ42 compared to placebo, suggesting some biochemical response despite the lack of clinical efficacy.
  • There was no significant difference in the accumulation of aggregated tau on PET between the gantenerumab and placebo groups.
  • Amyloid-related imaging abnormalities with edema were observed in nearly 25% of the gantenerumab recipients, with symptomatic cases in 5%.

“Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer disease.”
– Dr. Randall J. Bateman, Washington University School of Medicine, St. Louis, Missouri

More on Cognitive Health/Memory

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form